Jump to content

Laura Soucek

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 17:24, 19 December 2020 (Task 18 (cosmetic): eval 16 templates: del empty params (8×); del |url-status= (1×);). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Laura Soucek
Born
Velletri
Alma materSapienza University of Rome
University of California, San Francisco
Scientific career
InstitutionsVall d'Hebron Institute of Oncology, ICREA, UAB

Laura Soucek (born 1973) is a Group Leader at VHIO (the Vall d'Hebron Institute of Oncology), Research Professor at ICREA, and CEO of Peptomyc S.L. She works on the Myc oncoprotein, the deregulation of which occurs during almost all cancers. Soucek has designed a dominant negative variant, Omomyc, which allows her to investigate the benefits of inhibiting Myc in cancer.

Early life and education

Soucek was born in Velletri on the outskirts of Rome.[1] She studied biology at the Sapienza University of Rome and graduated in 1996.[2] After earning her bachelor's degree Soucek moved to the National Research Centre in Rome, where she started a doctorate in genetics and molecular biology.[3] During this time she started researching novel treatments for cancer.[4] Soucek completed her PhD in 2001 and joined the University of California, San Francisco as a postdoctoral fellow. She was appointed as an Assistant Researcher in the laboratory of Gerard Evan in 2006. She returned to Europe in 2011, joining VHIO (Vall d'Hebron Institute of Oncology).[4]

Research and career

Soucek is Head of the Mouse Models of Cancer Therapies Group at VHIO and was the first woman and non-Spanish national to be appointed as Principal Investigator. She was promoted to Research Professor at ICREA in 2014. In 2014 she founded a spin-out company, Peptomyc S.L..[5][6] In 2015 she was made Associate Professor at the Autonomous University of Barcelona.[7] Her research considers the Myc oncoprotein, a protein that cancer cells appear to depend on but had previously been considered too difficult to target.[2][8] She has demonstrated that inhibition of Myc can have a therapeutic index in mouse models of cancer, causing minimal side effects in regular tissues. Soucek created Omomyc, a dominant negative form of Myc that can inhibit the oncogene without causing adverse impacts.[6][9] As Omomyc is tolerated by mice and has anti-tumour activity, Soucek has been developing an efficient and safe drug version.[6] She believes that inhibition of Myc can force the immune system to wake up, and kill cancer from the inside and outside.[8] Peptomyc have demonstrated that Omomyc can be used against non-small-cell lung carcinoma.[6]

In 2019 Peptomyc was awarded the European Institute of Innovation and Technology Public Prize.[10][11] She has successfully raised over €4 million in venture capital from the EIT health community.[4][12] She featured in a FC Barcelona commercial to advertise the 2019/2020 season kit. The advert paid homage to people who have contributed to the community of Barcelona.[13]

Selected publications

Her publications include;

  • Soucek, Laura (2008). "Modelling Myc inhibition as a cancer therapy". Nature. 455 (7213): 679–683. Bibcode:2008Natur.455..679S. doi:10.1038/nature07260. PMC 4485609. PMID 18716624.
  • Soucek, Laura (2007). "Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors". Nature Medicine. 13 (10): 1211–1218. doi:10.1038/nm1649. PMID 17906636.
  • Soucek, Laura (2013). "Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice". Genes & Development. 27 (5): 504–513. doi:10.1101/gad.205542.112. PMC 3605464. PMID 23475959.

References

  1. ^ "ICREA". www.icrea.cat. Retrieved 2019-11-04.
  2. ^ a b Interviews, Clara Rodríguez Fernández-09/05/2019 4 mins- (2019-05-09). "A 20-Year Journey to Nail Down an Undruggable Cancer Target". Labiotech.eu. Retrieved 2019-11-05.{{cite web}}: CS1 maint: numeric names: authors list (link)
  3. ^ Whitfield, Jonathan; Soucek, Laura (2019-08-01). "Editorial overview: Peptides in cancer". Current Opinion in Pharmacology. 47: iii–v. doi:10.1016/j.coph.2019.06.001. ISSN 1471-4892. PMC 6768800. PMID 31257021.
  4. ^ a b c "La mujer que quiere (y va a intentar) acabar con el cáncer". Diario Sur (in Spanish). 2018-12-08. Retrieved 2019-11-04.
  5. ^ peptomyc_2015. "Team". Peptomyc (in European Spanish). Retrieved 2019-11-04.{{cite web}}: CS1 maint: numeric names: authors list (link)
  6. ^ a b c d "El inhibidor de Myc, Omomyc, entra en la recta final previa al ensayo clínico". Vall d'Hebron Barcelona Hospital Campus (in Spanish). 2019-10-04. Retrieved 2019-11-04.
  7. ^ "Laura Soucek: "Starting up a company was the most logical decision to translate 20 years of research into a real therapeutic opportunity" | Biocat". www.biocat.cat. Retrieved 2019-11-05.
  8. ^ a b "Laura Soucek: "Con el fármaco matamos al cáncer desde dentro y desde fuera"". Redacción Médica (in Spanish). Retrieved 2019-11-04.
  9. ^ "Así funciona el Omomyc, el nuevo fármaco contra el cáncer". La Vanguardia. 2019-03-26. Retrieved 2019-11-04.
  10. ^ "Pushing MYC inhibition closer to the clinic". medicalxpress.com. Retrieved 2019-11-05.
  11. ^ "Individuals make innovation a reality". The Parliament Magazine. 2018-11-26. Retrieved 2019-11-05.
  12. ^ "EIT Health projects focused on women". EIT. Retrieved 2019-11-04.
  13. ^ "FC Barcelona Premieres New Jersey in Spot With Music by Area21: Watch". Billboard. Retrieved 2019-11-05.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Laura_Soucek&oldid=995176102"